NDAORAL-21TABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 1/80 21 is an oral combination contraceptive containing mestranol (estrogen) and norethindrone (progestin) in a 21-day tablet regimen. It prevents ovulation and alters cervical mucus to provide contraceptive efficacy. This is a foundational hormonal contraceptive product from Johnson & Johnson.
Pre-Launch
Pre-launch status indicates early-stage commercial planning; team size and budget allocation remain undefined pending regulatory clearance.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ORTHO-NOVUM 1/80 21 offers exposure to Women's Health and contraceptive market dynamics, a stable therapeutic category with high patient volumes. Pre-launch positioning means career growth depends on successful market entry execution and competitive differentiation in a crowded oral contraceptive landscape.
Brand ManagerField Sales Representative
Worked on ORTHO-NOVUM 1/80 21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.